-+ 0.00%
-+ 0.00%
-+ 0.00%
Novartis pelabresib combination shows sustained clinical effects at 144 weeks in Phase III myelofibrosis trial
Share
Listen to the news
Novartis pelabresib combination shows sustained clinical effects at 144 weeks in Phase III myelofibrosis trial
  • Novartis will present nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium and American Society of Hematology meeting.
  • Pelabresib data scheduled for December 13 show sustained clinical effects with ruxolitinib in previously untreated myelofibrosis patients.
  • Scemblix findings scheduled for December 14 show sustained tolerability advantages over nilotinib in newly diagnosed chronic myeloid leukemia.
  • Kisqali results scheduled for December 9 examine long-term treatment outcomes across nodal subgroups in HR-positive, HER2-negative early breast cancer.
  • RAE346's first clinical results since its acquisition from Synnovation will be presented December 9, covering advanced cancers including breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180100OMX_____CNEWS_EN_GNW1001304182_en) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending